SUMMARY In a previous clinical study we demonstrated that tocainide is effective in the suppression of ventricular ectopic depolarizations (VEDs) after single oral doses. This information provided the basis for evaluating this drug's antiarrhythmic efficacy after multiple dose administration according to a loadingmaintenance regimen. Twelve patients with stable VEDs were given loading doses of tocainide (400-600 mg) with maintenance doses every 12 hours. Every 48 hours the dose was increased until either arrhythmia suppression to < 25% of VED frequency during placebo administration or side effects occurred. 
SUMMARY In a previous clinical study we demonstrated that tocainide is effective in the suppression of ventricular ectopic depolarizations (VEDs) after single oral doses. This information provided the basis for evaluating this drug's antiarrhythmic efficacy after multiple dose administration according to a loadingmaintenance regimen. Twelve patients with stable VEDs were given loading doses of tocainide (400-600 mg) with maintenance doses every 12 hours. Every 48 hours the dose was increased until either arrhythmia suppression to < 25% of VED frequency during placebo administration or side effects occurred. Computer analysis of 12-hr telemetric ECGs taken 24-36 hr after each dosage increment ALTHOUGH AN EXCELLENT antiarrhythmic drug, lidocaine has pharmacokinetic characteristics (a high hepatic clearance and thus poor systemic bioavailability, and a short half-life) that preclude its effective oral use.' Accordingly, lidocaine congeners with improved oral availability have been investigated for antiarrhythmic efficacy. Studies in animals demonstrated antiarrhythmic efficacy and high oral bioavailability for one such compound, tocainide hydrochloride.2 (Previous publications have referred to tocainide as W-36095 (Astra) or 2-amino-2',6'-propionoxylidide hydrochloride.) Our previous evaluation of single oral doses of tocainide in patients with stable ventricular ectopic depolarizations (VEDs) found it to have prolonged antiarrhythmic efficacy, good oral bioavailability and a mean elimination half-life (t X3) of 14.6 hours.3 The purpose of this study was to extend this initial information by assessment of the antiarrhythmic efficacy and pharmacokinetics of multiple-dose regimens designed for maintenance therapy.
Methods and Materials Twelve consenting volunteer patients with stable VEDs were admitted to the Clinical Research Center (CRC) of Vanderbilt University Hospital. All patients were ambulatory while in the hospital and under constant electrocardiographic monitoring. A Hewlett-Packard Model 78100A telemetry system transmitted ECG signals to the hospital coronary care unit and also to an Ampex Model FR 1200 tape recorder. Twelve hour segments of ECG data were taped for computer analysis. All medications were discontinued on admission with the exception of cardiac glycosides or anticoagulants. Dietary sodium was controlled at 100 meq daily.
documented effective suppression (76-95%) in 8 of 12 patients. Those subjects demonstrating suppression were randomly assigned to a cross-over study of 
Subjects
The following criteria were used in excluding patients from this study: age less than 21 or greater than 75; premenopausal female patients without surgical sterility; unstable concurrent illness; arrhythmia due to digitalis intoxication, electrolyte disturbance, correctable blood gas abnormality or acute myocardial infarction; arrhythmia requiring acute effective therapy; sick sinus syndrome; ventricular pre-excitation; atrial fibrillation or flutter; atrial tachycardia; bundle branch block; grade 2 or greater A-V block; myocardial infarction within the previous six weeks; unstable angina; pulmonary edema or greater than 2+ peripheral edema if attributed to heart failure; serum urea nitrogen > 30 mg%; and known allergy to lidocaine or local anesthetics.
Nine males and three females described in table I participated as volunteers in this study. Patients with complicating illnesses or NYHA cardiac status class IV were excluded. All patients had stable VEDs (> 500 per 12 hour period) and were able to have any established antiarrhythmic therapy discontinued for this study. Patients were accepted if their VED frequency was relatively constant throughout the 12 hours of observation. Patients with 15 consecutive minutes free of ectopic beats during control observations were excluded. All but three patients in this study had greater than 4 VEDs/min for every hour of observation during initial placebo therapy. Two of these three had a coefficient of variation for the hourly VED counts of 18 and 29% and more than 1 PVC/min for every hour analyzed. The only patient who had wide variation in hourly VED frequency was RM who had a constant daily pattern in which his VED frequency peaked at 12 noon and 6 p.m. with troughs at 9 a.m., 3 p.m., and 9 p.m. A minimum of 25 VEDs were counted in one hour and a maximum of 1235 in another hour; his hourly coefficient of variation was 103% for all pre-drug placebo data. Six of the twelve patients had known coronary vascular disease and had experienced a myocardial infarction two or more years prior to participation in this study. One patient had stable obstructive and restrictive lung disease but did not require bronchodilator therapy during the study. Three patients had mild essential hypertension; all became normotensive during the hospitalization while receiving a diet containing 100 meq SUPPRESSION OF VEDs BY TOCAINIDE/Woosley et al. sodium. Extensive medical evaluation including coronary arteriography was unable to discern an etiology for the arrhythmia in two other patients. Seven of the twelve patients had been found to be resistant to one or more antiarrhythmic drugs prior to being referred to this study. Ten of the patients had responded to quinidine prior to participating in this study but two had been unresponsive to quinidine, procainamide and propranolol.
Medication
Tocainide HCl as 50 mg and 200 mg tablets and an identical placebo were supplied by Astra Pharmaceutical Products and administered 30 minutes after a meal of varying composition.
Study Procedure
Patients were admitted to the CRC and allowed to stabilize without antiarrhythmic therapy for at least two days. Once the patient's arrhythmias were stable, responsiveness to lidocaine was determined in the following manner. The number of VEDs were counted for six consecutive five-minute intervals and the mean five-minute incidence determined. A bolus of 50 mg of lidocaine was given STAGE I intravenously followed by injections of 25 mg every ten minutes until either a total dose of 125 mg or 75% reduction in VEDs occurred. The response to lidocaine was evaluated by determining the percent reduction in the number of VEDs in each interval from the control mean. Lack of response was not a criterion for exclusion from the subsequent study.
The response to tocainide was determined in two stages (see fig. 1 ). Stage I was a placebo-controlled single-blind study in which patients were treated with increasing dosages of tocainide after an initial placebo period. Each patient was given an initial loading dose (400-600 mg) followed by a smaller maintenance dosage on a 12 hourly regimen. If antiarrhythmic efficacy was not seen after 48 hours, a fractional loading dose was administered in order to bring the amount of drug in the body toward the next steady-state level. The dosage was increased every 48 hours until efficacy or an adverse effect was seen up to a maximum daily dosage of 20 mg/kg. If 75% or greater arrhythmia suppression occurred in Stage I, the patient entered Stage II which consisted of placebo and tocainide treatment periods of five days each, the sequence of which was randomly assigned. The dosage of tocainide was that determined to be effective during Stage I. All treatment periods were separated by two day periods to allow drug washout and dissipation of any drug effects. figure 2 . Arrhythmia suppression > 70% was present for only eight hours in some patients. Continuous suppression was seen in two of the eight patients. Their dosages (500 and 600 mg every 12 hr) were not significantly higher than the other patients. Figure 2 compares the mean number of VEDs in each hour after dosing for the eight patients during the control and treatment periods. As can be seen, there is a significant increase in VED frequency after the eighth hour indicating more complete suppression might be feasible for some patients on an eight-hourly dosage regimen. Increased duration of effect might be possible by increasing the 12-hourly dosage, but peak blood levels would be excessive in many patients. Since the minimum effective range of plasma concentrations is between 3.5 and 7 ,ug/ml and CNS toxicity occurs at plasma levels between 10 and 15 ug/ml, it is difficult to maintain therapeutic plasma levels on a q 12 hr regimen without reaching excessive levels at the peak of drug absorption. Importantly though, these side effects are readily reversible and quite tolerable. They serve as reliable evidence that the drug concentration has exceeded those levels usually associated with antiarrhythmic efficacy and if efficacy has not been seen when they appear, further dosage increase would be unwarranted. Administration of tocainide on an eight-hourly regimen might allow less variation in plasma levels and maintain the level within the therapeutic window throughout the entire dosage interval.
Pharmacokinetic studies in normal volunteers" found the elimination half-life to be 11 hours whereas our previous studies of patients with cardiac arrhythmias and our present study found the mean t,fl to be 14.6 and 16.1 hours, respectively. These data suggest that drug elimination may be different in these patients compared to normal volunteers.
No undue accumulation occurred during the five-day Stage II treatment period on a 12-hourly dosage regimen.
In agreement with our previous findings3 there is a positive correlation between the antiarrhythmic efficacy of tocainide and lidocaine. Comparison of the therapeutic range of plasma levels for the two drugs indicates that tocainide may have only half the potency of lidocaine since lidocaine appears to have efficacy in the range of plasma levels from 1.5 -5 ,ug/mlr and levels of 3.5-10 are required for tocainide. Plasma protein bindings of the two are very similar (about 50%). 1" 11 Tocainide appears to be a comparatively safe and effective agent for chronic suppression of VEDs. Because troublesome but reversible CNS side effects occur during peak blood levels and antiarrhythmic effects last only eight hours in some patients, an 8-hourly regimen should be evaluated in future studies.
